ফিনল্যান্ড -
ফিনিশ -
Fimea (Suomen lääkevirasto)
miochol-e 10 mg/ml jauhe ja liuotin instillaatioliuosta varten, silmän sisään
dr. gerhard mann chem.-pharm. fabrik gmbh - acetylcholine chloride - jauhe ja liuotin instillaatioliuosta varten, silmän sisään - 10 mg/ml - asetyylikoliini
ফিনল্যান্ড -
ফিনিশ -
Fimea (Suomen lääkevirasto)
urecholine chlorid 5 mg tabletti
merck & co. inc. - bethanecholi chloridum - tabletti - 5 mg - betanekoliini
ফিনল্যান্ড -
ফিনিশ -
Fimea (Suomen lääkevirasto)
urecholine 5 mg tabletti
merck sharp & dohme b.v. - bethanecholi chloridum - tabletti - 5 mg - betanekoliini
ইউরোপীয় ইউনিয়ন -
ফিনিশ -
EMA (European Medicines Agency)
yselty
theramex ireland limited - linzagolix choline - leiomyoma - aivolisäkkeen ja hypotalamuksen hormonit ja analogit - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
ইউরোপীয় ইউনিয়ন -
ফিনিশ -
EMA (European Medicines Agency)
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
ফিনল্যান্ড -
ফিনিশ -
Fimea (Suomen lääkevirasto)
prazitel plus 50 mg / 144 mg / 150 mg tabletti
chanelle pharmaceuticals manufacturing limited - febantel, praziquantel, pyrantel embonate - tabletti - 50 mg / 144 mg / 150 mg - pratsikvanteeli
ইউরোপীয় ইউনিয়ন -
ফিনিশ -
EMA (European Medicines Agency)
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - immunosuppressantit - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
ফিনল্যান্ড -
ফিনিশ -
Fimea (Suomen lääkevirasto)
proline
bayer ag - tiabendazolum - annosjauhe - tiabendatsoli
ফিনল্যান্ড -
ফিনিশ -
Fimea (Suomen lääkevirasto)
exproline vet 67 mg paikallisvaleluliuos
krka, d.d., novo mesto - fipronil - paikallisvaleluliuos - 67 mg - fiproniili